Why Prime Medicine Stock Is Soaring Today
Shares of Prime Medicine (NASDAQ: PRME) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m. ET and was up as much as 17% earlier in the day. The move up comes as the S 500 and Nasdaq Composite gained 0.4% and 0.7%, respectively.
The clinical-stage biotech unveiled a promising new preclinical program targeting a serious disorder of the lungs and liver.
Prime Medicine announced yesterday a new preclinical program for treating alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting lung and liver function. The announcement included plans to file an Investigational New Drug Application or Clinical Trial Application with the FDA by mid-2026.
Source Fool.com
